10024 Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Submission for OMB Review;

Comment Request; Evaluation of User

Satisfaction With NIH Internet Sites

SUMMARY: Under the provisions of

Section 3507(a)(1)(D) of the Paperwork

Reduction Act of 1995, the National

Institutes of Health (NIH) has submitted

to the Office of Management and Budget

(OMB) a request to review and approve

the information collection listed below.

This proposed information collection

was previously published in the Federal

Register on March 6, 2000, in Volume

65, No. 44, pages 11787–11788, under

the title ‘‘Request for Generic Clearance

to Collect Customer Survey Data

Pertaining to NIH Internet Sites,’’ and

allowed 60 days for public comment. No

public comments were received. The

purpose of this notice is to allow an

additional 30 days for public comment.

The NIH may not conduct or sponsor,

and the respondent is not required to

respond to, an information collection

that has been extended, revised, or

implemented after October 1, 1995,

unless it displays a currently valid OMB

control number.

Proposed Collection

Title: Evaluation of User Satisfaction

with NIH Internet Sites. Type of

Information Collection Request: New.

Need and Use of Information Collection:

Executive Order 12862 directs agencies

that provide significant services directly

to the public to survey customers to

determine the kind and quality of

services they want and their level of

satisfaction with existing services. With

this submission, the NIH, Office of

Communications and Public Liaison,

seeks to obtain OMB’s generic approval

to conduct customer satisfaction

surveys. Since the late 1980’s, the NIH

has seized the opportunity to

disseminate information and materials

via the Internet. Today, rapid

technological changes of the WWW

warrant on-going constituent and

resource analysis. With survey

information, the NIH is enabled to serve,

and respond to, the ever-changing

demand by the public. The ‘public’

includes individuals (such as patients,

educators, students, etc.) and interested

communities (such as national or local

organizations/institutions) and business.

Survey information will augment

current Web content, delivery, and

design research which is used to

understand the Web user, and more

specifically, the NIH user community.

Primary objectives are to (1) Classify

NIH Internet users; (2) summarize and

better understand customer needs; and

(3) quantify the effectiveness/efficiency

of current tools and delivery. Overall,

the Institutes, Centers, and Offices of the

NIH will use the survey results to

identify strengths and weaknesses in

current Internet strategies. Findings will

help to (1) Understand user community

and how to better serve Internet users;

(2) discover areas requiring

improvement in either content or

delivery; (3) realize how to align Web

offerings with identified user need(s);

and (4) explore methods to offer and

deliver information with efficacy and

equity. Frequency of Response: Annual

[As needed on an on-going and,

possibly, concurrent basis (by Institute,

Center, or Office)]. Affected Public:

Users of the Internet. Primarily, this is

an individual at their place(s) of access

including, but not limited to, home or/

and work environments. Type of

Respondents: Public users of the NIH

Internet site, www.nih.gov, which may

include organizations, medical

researchers, physicians and other health

care providers, librarians, students, as

well as individuals of the general

public. Estimated Number of

Respondents: 104,000. Number of

Respondents Per Respondent: 1.

Average Burden Hours Per Response:

0.084. Burden Hours Requested: 8684.

Total annualized cost to respondents is

estimated at $116,105. There are also no

capital costs, operating costs and/or

maintenance costs to report.

SURVEY TITLE: WEB CUSTOMER SATISFACTION SURVEY—ANNUAL REPORTING BURDEN 1

[Web-based; Required for FEDERAL REGISTER requests under PRA, Paperwork Reduction Act.]

Survey area No.

respondents

Frequency

of response

Avg. burden

per

response

(hours)

Burden

hours

NIH Organization-wide (1 entity) ..................................................................................... 4,000 334

Overall customer satisfaction ................................................................................... 2,000 1 0.1002 200

Specific indicator: Top-level/Entry pages ................................................................. 1,000 1 0.0668 67

Specific indicator: Tools and initiatives .................................................................... 1,000 1 0.0668 67

Individual Institute/Office .................................................................................................. 100,000 8,350

Overall customer satisfaction ................................................................................... 50,000 1 0.1002 5,010

Specific indicator: Top-level/Entry pages ................................................................. 25,000 1 0.0668 1,670

Specific indicator: Tools and initiatives .................................................................... 25,000 1 0.0668 1,670

Total ............................................................................................................... 104,000 0.084 8,684

1Survey research firm, MediaMetrics, indicated 1,264,000 unique visitors to NIH sites in Dec, 1999. If fully implemented, an average month

would survey 8,600 users (less than 0.007 of total average unique visitors to NIH sites).

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) The accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

Ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) Ways to minimize the

burden of the collection of information

on those who are to respond, including

the use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request additional information on the

proposed collection of information

contact: Dennis Rodrigues, NIH Office of

Communications and Public Liaison,

9000 Rockville Pike, Bldg. 31, Rm.

2B03, Bethesda, Maryland 20892–2094,

Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices 10025

or call non toll-free at (301) 435–2932.

You may also e-mail your request to

dr3p@nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received within 30

days of the date of this publication.

Dated: February 1, 2001.

Anne Thomas,

Assoc. Director, Office of Communications

and Public Liaison, National Institutes of

Health.

[FR Doc. 01–3607 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases

(NIDDK): Opportunity for Cooperative

Research and Development

Agreements (CRADAs) to Develop

Monoclonal Antibodies and/or Other

Reagents and Products for Use in

Identifying the Dombrock Blood Group

Carrier Molecule Aimed at Improving

Blood Typing Practices Through

Molecular Means

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institute of

Diabetes and Digestive and Kidney

Diseases (NIDDK) of the National

Institutes of Health (NIH) is seeking

Licensee(s) and/or proposals in the form

of capability statements from potential

collaborators for a Cooperative Research

and Development Agreement (CRADA)

to develop monoclonal antibodies and/

or other reagents and products for use

in identifying the Dombrock blood

group carrier molecule. The U.S.

government-owned technology is

encompassed within U.S. Provisional

Patent Application Serial No. 60/

235,162, entitled ‘‘Identification of The

Dombrock Blood Group Glycoprotein as

a Polymorphic Member of The ADPRibosyltransferase Gene Family’’.

Pursuant to the Federal Technology

Transfer Act of 1986 (FTTA, 15 U.S.C.

3710; and Executive Order 12591 of

April 10, 1987, as amended by the

National Technology Transfer and

Advancement Act of 1995), the National

Institute of Diabetes and Digestive and

Kidney Diseases (NIDDK) of the

National Institutes of Health (NIH) of

the Public Health Service (PHS) of the

Department of Health and Human

Services (DHHS) seeks a Cooperative

Research and Development Agreement

(CRADA) with a pharmaceutical or

biotechnology company to develop

monoclonal antibodies and/or other

reagents for use in identifying the

Dombrock blood group carrier molecule.

The goals of the CRADA include the

rapid publication of research results and

timely commercialization of products or

methods that may result from the

research.

The potential Collaborator(s)

capability statement should provide

proof of expertise in blood typing

practices through molecular means

along with a brief commercialization

plan. The NIH also will consider

proposals from Collaborators with

demonstrated expertise in developing

kits designed to identify blood group

antibodies in recipients of transfused

blood or blood products.

DATES: Only written CRADA capability

statements received by the NIDDK on or

before March 30, 2001 will be

considered during the initial design

phase; confidential information must be

clearly labeled. Potential Collaborators

may be invited to meet with the

Selection Committee at the

Collaborator’s expense to provide

additional information. The Institute

may issue an additional notice of

CRADA opportunity during the design

phase.

FOR FURTHER INFORMATION CONTACT:

Capability statements should be

submitted to Dr. Michael W. Edwards,

Office of Technology Development,

National Institute of Diabetes and

Digestive and Kidney Diseases, National

Institutes of Health, BSA Building, Suite

350 MSC 2690, 9190 Rockville Pike,

Bethesda, MD 20814–3800; Tel: 301/

496–7778, Fax: 301/402–0535; Email:

mels@nih.gov.

SUPPLEMENTARY INFORMATION: A CRADA

is an agreement designed to enable

certain collaborations between

Government laboratories and nonGovernment laboratories. It is not a

grant, and is not a contract for the

procurement of goods/services. The

NIDDK is prohibited from transferring

funds to a CRADA collaborator. Under

a CRADA, NIDDK can contribute

facilities, staff, materials, and expertise

to the effort. The collaborator typically

contributes facilities, staff, materials,

expertise, and funding to the

collaboration. The CRADA collaborator

receives an exclusive option to negotiate

an exclusive or non-exclusive license to

Government intellectual property rights

arising under the CRADA in a predetermined field of use and may qualify

as a co-inventor of new technology

developed under the CRADA.

Identification of the 25 known human

blood group molecules is of

fundamental importance for the fields of

erythroid cell biology and transfusion

medicine. The molecular description of

the ‘‘Dombrock’’ blood group system has

been determined. A candidate gene was

identified by in silico analyses of

approximately 5000 expressed sequence

tags (ESTs) from terminally

differentiating human erythroid cells.

Transfection experiments demonstrated

specific binding of anti-Dombrock and

confirmed glycosylphosphatidylinositol

membrane attachment.

Currently, reagents may not be

available to readily type all blood using

serology. The information derived by

this invention of the Dombrock blood

group carrier gene can be used to type

the human blood supply. The public

health need is to improve the blood

typing practices through molecular

means and thereby prevent clinical

problems associated with improperly

cross-matched blood.

Capability Statements

A Selection Committee will utilize the

information provided in the

‘‘Collaborator Capability Statements’’

received in response to this

announcement to help in its

deliberations. It is the intention of the

NIDDK that all qualified Collaborators

have the opportunity to provide

information to the Selection Committee

through their capability statements. The

Capability Statement should not exceed

10 pages and should address the

following selection criteria:

(1) The statement should provide

specific details of the method to be

utilized in the development of the

monoclonal antibody to the Dombrock

molecule.

(2) The statement should include a

detailed plan demonstrating the ability

to provide sufficient quantities of the

agent in a timely manner for the

duration of the study.

(3) The statement may include outline

outcome measures of interest to the

Collaborator. The specifics of the

proposed outcome measures and the

proposed support should include but

not be limited to the following:

monoclonal development expertise,

specific funding commitment to support

the advancement of scientific research,

personnel services, facilities,

equipment, or other resources that

would contribute to the conduct of the

commercial development.

(4) The statement must address

willingness to promptly publish

research results and ability to be bound